USE OF ESTRADIOL VALERATE OR 17&bgr; -ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY FOR MAINTAINING AND/OR INCREASING THE FEMALE LIBIDO

摘要

The invention relates to the use of estradiol valerate or estradiol in combination with 17α-cyanomethyl-17-&bgr; hydroxyestra-4,9-dien-3-one (dienogest) in a multiphase or single-phase combination preparation for oral therapy for maintaining and/or increasing the female libido, optionally also in unity with oral contraception. The total daily dose units of the multiphase combination and of the pharmaceutically acceptable placebo or of the single-phase combination and the active-ingredient-free and placebo-free daily dose units correspond to 28 days.